| abstract |
The present invention relates to an immunosuppression recovery oligonucleotide comprising 12 to 18 nucleotides, wherein at least one nucleotide is modified, and the oligonucleotide is compatible with the exonucleosidase of SEQ ID NO. 1 (human) ( NTPdase; CD73) nucleic acid sequence hybridization, wherein the oligonucleotide inhibits CD39 expression by at least 50%. The present invention also relates to pharmaceutical compositions comprising such oligonucleotides. |